Details of the Drug

General Information of Drug (ID: DMWA2DZ)

Drug Name
Berotralstat
Synonyms
UNII-XZA0KB1BDQ; XZA0KB1BDQ; 1809010-50-1; BCX7353; BCX-7353; Berotralstat (USAN); Berotralstat [USAN]; 1-[3-(aminomethyl)phenyl]-N-(5-{(R)-(3-; cyanophenyl)[(cyclopropylmethyl)amino]methyl}-2-; fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-; Orladeyo; Berotralstat [INN]; Berotralstat [USAN:INN]; SCHEMBL21974728; GTPL11347; WHO 10907; D11673; 1-(3-(Aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1H-pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl); 1H-Pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-; 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
Indication
Disease Entry ICD 11 Status REF
Hereditary angioedema 4A00.14 Approved [1]
ATC Code
B06AC06: Berotralstat
B06AC: Drugs used in hereditary angioedema
B06A: OTHER HEMATOLOGICAL AGENTS
B06: OTHER HEMATOLOGICAL AGENTS
B: BLOOD AND BLOOD FORMING ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 562.6
Logarithm of the Partition Coefficient (xlogp) 4.5
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 2770 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 158 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [2]
Elimination
Following a single oral dose administration of 300 mg radiolabeled berotralstat, approximately 9% of the drug was excreted in the urine, where 1.8 to 4.7% of the total radiolabeled compound accounted for the unchanged parent drug [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 39 - 152 hours [2]
Metabolism
The drug is metabolized via the CYP2D6 and CYP3A4 [2]
Chemical Identifiers
Formula
C30H26F4N6O
IUPAC Name
2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
Canonical SMILES
C1CC1CN[C@@H](C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N
InChI
InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1
InChIKey
UXNXMBYCBRBRFD-MUUNZHRXSA-N
Cross-matching ID
PubChem CID
137528262
ChEBI ID
CHEMBL5189739
CAS Number
1809010-50-1
UNII
XZA0KB1BDQ
DrugBank ID
DB15982
TTD ID
DQ1S0B
ACDINA ID
D00877
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasma kallikrein (KLKB1) TTMF8H9 KLKB1_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Crospovidone E00626 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Berotralstat eq 110mg base capsule eq 110mg base Capsule Oral
Berotralstat eq 150mg base capsule eq 150mg base Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 FDA Approved Drug Products: ORLADEYO (berotralstat) capsules, for oral use